Patents by Inventor Xiao-Tao Chen

Xiao-Tao Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof
    Publication number: 20140336123
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: August 1, 2014
    Publication date: November 13, 2014
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Opioid receptor ligands and methods of using and making same
    Patent number: 8835488
    Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: September 16, 2014
    Assignee: Trevena, Inc.
    Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C. K. Yuan
  • ?-arrestin effectors and compositions and methods of use thereof
    Patent number: 8809260
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: August 19, 2014
    Assignee: Trevena, Inc.
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • ?-arrestin effectors and compositions and methods of use thereof
    Patent number: 8796204
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 5, 2014
    Assignee: Trevena, Inc.
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof
    Publication number: 20140005114
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: June 25, 2013
    Publication date: January 2, 2014
    Applicant: Trevena, Inc.
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Opioid Receptor Ligands and Methods of Using and Making Same
    Publication number: 20130331408
    Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 12, 2013
    Applicant: Trevena, Inc.
    Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C.K. Yuan
  • BETA-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20130274176
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 17, 2013
    Applicant: Trevena, Inc.
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Beta-Arrestin Effectors and Compositions and Methods of Use Thereof
    Publication number: 20130196902
    Abstract: This application describes compounds acting as, for example, ?-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: January 31, 2013
    Publication date: August 1, 2013
    Applicant: Trevena, Inc.
    Inventors: Dennis Yamashita, Xiao Tao Chen
  • ?-arrestin effectors and compositions and methods of use thereof
    Patent number: 8486885
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: July 16, 2013
    Assignee: Trevena, Inc.
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME
    Publication number: 20120245181
    Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
    Type: Application
    Filed: March 23, 2012
    Publication date: September 27, 2012
    Applicant: Trevena, Inc.
    Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C.K. Yuan
  • Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof
    Publication number: 20100184701
    Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
    Type: Application
    Filed: December 28, 2009
    Publication date: July 22, 2010
    Inventors: Dennis Yamashita, Xiao-Tao Chen
  • Met kinase inhibitors
    Patent number: 7547782
    Abstract: The present invention is directed to compounds having the formula I or II: including salts thereof, and methods for using them for the treatment of cancer.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: June 16, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Xiao-Tao Chen, David K. Williams, John S. Tokarski, Robert F. Kaltenbach
  • Fused heterocyclic kinase inhibitors
    Patent number: 7439246
    Abstract: In general, the instant invention comprises compounds of Formulas I and II including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: October 21, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Zhong Chen, Tram N. Huynh, Wayne Vaccaro, Xiao-Tao Chen, Kyoung S. Kim, Zhen-wei Cai
  • Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 7211671
    Abstract: The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein A, L R1, R2, R3 and R4 are defined in the present specification, which are useful as selective inhibitors of MMP, TACE, aggrecanase or a combination thereof. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: May 1, 2007
    Assignee: Bristol Myers Squibb Company
    Inventors: James Sheppeck, John L. Gilmore, Xiao-Tao Chen, Xiaohua He
  • MET kinase inhibitors
    Publication number: 20070078140
    Abstract: The present invention is directed to compounds having the formula I or II: including salts thereof, and methods for using them for the treatment of cancer.
    Type: Application
    Filed: September 28, 2006
    Publication date: April 5, 2007
    Inventors: Robert Borzilleri, Xiao-Tao Chen, David Williams, John Tokarski, Robert Kaltenbach
  • Pyrrolotriazine kinase inhibitors
    Patent number: 7173031
    Abstract: In general, the instant invention comprises compounds of Formulas I and II including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Zhong Chen, John T. Hunt, Tram Huynh, Michael A. Poss, Gretchen M. Schroeder, Wayne Vaccaro, Tai W. Wong, Xiao-Tao Chen, Kyoung S. Kim
  • ?-O-linked glycoconjugates, methods of preparation and uses thereof
    Patent number: 7160856
    Abstract: The present invention provides novel ?-O-linked glycoconjugates such as ?-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the ?-O-linked glycoconjugates.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: January 9, 2007
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Dalibor Sames, Samuel Hintermann, Xiao Tao Chen, Jacob B. Schwarz, Peter Glunz, Govindaswami Ragupathi, Philip O. Livingston, Scott Kuduk, Lawrence Williams
  • Fused heterocyclic kinase inhibitors
    Publication number: 20060211695
    Abstract: In general, the instant invention comprises compounds of Formulas I and II including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.
    Type: Application
    Filed: December 1, 2005
    Publication date: September 21, 2006
    Inventors: Robert Borzilleri, Zhong Chen, Tram Huynh, Wayne Vaccaro, Xiao-Tao Chen, Kyoung Kim, Zhen-wei Cai
  • Modulators of the glucocorticoid receptor and method
    Patent number: 6995181
    Abstract: Novel non-steroidal compounds are provided which are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders, and have the structure where Z is CONR1R2 or CH2NR1R2 and where R, Ra, Rb, Rc, Rd, Z, A and B are defined herein.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: February 7, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Wayne Vaccaro, Bingwei Vera Yang, Soong-Hoon Kim, Tram Huynh, David R. Tortolani, Kenneth J. Leavitt, Wenying Li, Arthur M. Doweyko, Xiao-Tao Chen, Lidia Doweyko
  • Pyrrolotriazine kinase inhibitors
    Publication number: 20060004006
    Abstract: In general, the instant invention comprises compounds of Formulas I and II including pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.
    Type: Application
    Filed: June 24, 2005
    Publication date: January 5, 2006
    Inventors: Robert M. Borzilleri, Zhong Chen, John T. Hunt, Tram Huynh, Michael A. Poss, Gretchen M. Schroeder, Wayne Vaccaro, Tai W. Wong, Xiao-Tao Chen, Kyoung KIm